Entering Brazil with medical devices means dealing with ANVISA, local representatives, and market-specific regulatory expectations.
We help international manufacturers structure a clear authorization pathway, organize existing evidence into a Brazil-ready package, align key documents in Portuguese, and coordinate with local partners — reducing rework and regulatory back-and-forth.










Brazil market access & ANVISA authorization support
Structured, Brazil-ready documentation and strategy
Coordination with local partners and stakeholders
Dedicated regulatory and market access support for Brazil is especially valuable when your team needs clarity, predictability, and alignment across regions and partners.
You receive a Brazil-specific market access strategy combined with a practical, ANVISA-oriented documentation and coordination package that your internal teams and local partners can actively use.
Preparation and support for UDI/Devices entries using your existing Basic UDI-DI, UDI-DI, UDI-PI, and Annex VI data. We structure your information for the module, highlight obvious inconsistencies, and guide you through entering and saving records in EUDAMED.
Preparation and support for UDI/Devices entries using your existing Basic UDI-DI, UDI-DI, UDI-PI, and Annex VI data. We structure your information for the module, highlight obvious inconsistencies, and guide you through entering and saving records in EUDAMED.
Preparation and support for UDI/Devices entries using your existing Basic UDI-DI, UDI-DI, UDI-PI, and Annex VI data. We structure your information for the module, highlight obvious inconsistencies, and guide you through entering and saving records in EUDAMED.
A stepwise approach that starts from your existing regulatory evidence and results in a Brazil-ready documentation package with clearly defined coordination across all stakeholders.
We keep the service precisely defined so your internal team, Sobel, and your partners in Brazil understand who does what—and where additional services might be needed.
Consulting and documentation support only. We do not design UDI schemes, do not create Annex VI data, do not select issuing agencies, and do not act as a notified body, importer, or label designer. You remain responsible for UDI assignment, Annex VI content, technical documentation, and all formal submissions in EUDAMED.
Typical situations where appointing a BRH becomes essential for Brazil market access:
In Brazil, a locally established legal entity typically acts as the formal counterpart to ANVISA. We support by preparing and structuring the documentation and by coordinating the interface so your local partner can work with a clear, coherent package.
Medical devices placed on the Brazilian market generally need to follow ANVISA’s regulatory framework, with different routes and expectations depending on the device type and risk profile. We help you understand which path applies to your portfolio.
In many cases, yes. Approvals and evidence from other regions (e.g. EU, US) are valuable starting points. We focus on reusing and adapting what you have, while addressing the specific needs of the Brazilian system.
For Brazil, labels and IFU must be available in Portuguese. We help align the Portuguese content with your intended purpose/claims and ensure consistency with the authorized scope in Brazil.
No consultancy can guarantee processing times, as they depend on ANVISA’s workload and internal processes. Our role is to prepare a complete, well-structured package and to support coordination and tracking to reduce avoidable delays.
If Brazil is part of your market expansion plans — or if ANVISA requirements currently feel fragmented — a structured, Brazil-focused regulatory perspective can reduce uncertainty and accelerate decision-making.
We would love to speak with you.
Feel free to reach out using the below details.
To provide the best experiences, we use technologies such as cookies to store and/or access device information. Consenting to these technologies allows us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may negatively affect certain features and functions.